Back to all studies
RecruitingNCT06706232

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolarity II Depression and Suicidality

This study is recruiting. It focuses on bipolarity and currently lists participation information in the United States.

Bipolarity, Depression, ...DrugFrom 25 Years to 70 Years
Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT06706232. We help you review the study, but cannot decide medical eligibility.
In plain English

Key information made simple

What is this study testing?

This study is testing whether Psilocybin may be useful for adults experiencing bipolarity.

What would participation involve?

Participants may receive Psilocybin, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in United States.

Who is it mainly for?

This study appears to be mainly for adults with bipolarity.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

What to expect

Your next step

The official record suggests in-person participation through a university, with sites including The University of Texas Health Science Center at Houston. Participation appears to involve questionnaires, interviews, or regular check-ins about day-to-day experience. The main fit is usually being able to understand the study and consent and matching the main diagnosis, while common reasons not to take part include safety concerns that need urgent care first. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: July 7, 2025
Recruitment status
Recruiting
Estimated enrollment
Not clearly listed
Sponsor
The University of Texas Health Science Center, Houston
Sponsor type
University
Study type
Drug
Intervention type
Medication / drug, Psychotherapy / behavioral intervention
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 25 Years to 70 Years
Official registry ID
NCT06706232
Official title
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT06706232. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular follow-up, often through questionnaires or interviews.

Requires travel, with in-person participation in United States.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Psilocybin, Therapeutic Support. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.

Who might this study be for?

This study may concern people with bipolarity; age range: From 25 Years to 70 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by The University of Texas Health Science Center, Houston, which appears to be a university. The listed contact or investigator is The University of Texas Health Science Center, Houston, affiliated with The University of Texas Health Science Center, Houston. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The registry indicates that this study is currently recruiting. This does not mean you are eligible: the study team must confirm the criteria, available locations, and next steps.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me